A pilot study was performed to establish the digital image analysis plan using commercially available bladder cancer samples. CD8+ cells (tumor but not in stroma, middle), immune desert (absence of CD8+ cells in tumor and in stroma, bottom). Dotted line represents margin between tumor and stroma in the tumor (T) and stroma (S) compartments.

**Key Conclusions**
1. Efficacy and Safety of SRK-181
2. Immune characterization of response to SRK-181
3. Identification of a range of P-Smad2 nucleus marked cell or nucleus.

**Study Objectives**

**PART A**
- Evaluation of the safety and tolerability of SRK-181 (Part A).
- Evaluation of the PK of SRK-181.

**PART B**
- Evaluation of the safety and tolerability of SRK-181.
- Evaluation of the PK of SRK-181.
- Evaluation of efficacy and activity.
- Evaluation of immunotherapy activity.
- Evaluation of PK and ADA.

**Study Endpoints**
- **P-Smad2**
- **CD8+ T cells infiltrating tumor compartments

**Key Observations**
- Tumor regression
- Increased CD8+ T cells
- Decreased expression in P-Smad2
- Establishment of SRK-181 through multiplex IHC, NGS and additional blood-based biomarkers

**References**
2. Hussey, M., 2015. 3,4-Diethoxycinnamic acid.
3. Jeffrey G.主导的项目
4. TPS3146